All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the ALL Hub spoke with Bijal Shah, Moffitt Cancer Center, Tampa, US. We asked, Is the anti-CD19 CAR-T brexu-cel (formerly KTE-X19) safe and effective in B-ALL?
Is the anti-CD19 CAR-T brexu-cel safe and effective in B-ALL?
Shah evaluates safety and efficacy data from the ZUMA-3 study, evaluating brexu-cel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). He focuses on contextualizing these results in comparison with previously approved regimens.
KTE-X19 autologous anti-CD19 CAR T-cell therapy in patients with R/R B-ALL: Long-term phase I ZUMA-4 results
Despite the availability of novel therapies, clinical outcomes remain poor in the 10‒20% of pediatric and adolescent patients with B-cell...
What are the main advances in patient care that we are seeing with novel agents for leukemia?
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Guru Subramanian Guru Murthy, Medical College of Wisconsin, Milwaukee, US. We asked, What are...
Subscribe to get the best content related to ALL delivered to your inbox